ViiV Healthcare is an independent, global specialist HIV company established in 2009 with commitment to deliver innovative new options for the care and treatment of people living with HIV/AIDS. An essential element of our work is to develop our medicines through conducting clinical trials, where ...
ViiV Healthcare is an independent, global specialist HIV company established in 2009 with commitment to deliver innovative new options for the care and treatment of people living with HIV/AIDS. An essential element of our work is to develop our medicines through conducting clinical trials, where we...
Harmony P. Garges, M.D., Chief Medical Officer at ViiV Healthcare, said:“The exciting findings we’ll be presenting at AIDS 2024 continue to underscore our position as industry leaders in the development of long-acting and 2-drug regimens and our pioneering...
London, 28 October 2021 – ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive interim data from the CARISEL (Cabotegravir and Rilpivirine Implementation ...
Drug Profile Alternative Names:1265744; 744 LA Injection; APRETUDE; Apretude; CAB LA - ViiV Healthcare; Cabotegravir long acting; Cabotegravir sodium; GSK-1265744; GSK-1265744A; GSK-1265744B; GSK-744; GSK-744-LA; GSK1265744 LAP; S-265744; S-265744B; S/GSK-1265744; S/GSK1265744 LAP...
Register with us to use ViiV Healthcare’s authentication services; Use our websites, apps and systems; Share or use your social media profile to contact ViiV Healthcare; Sign up with us to receive promotional material; Enter a contest or competition organised by ViiV Healthcare; Get in touch...
ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shiono...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from its phase I study showing that an investigational formulation...
Kimberly Smith, MD, Head of Global Research & Medical Strategy at ViiV Healthcare,said: “With HIV now considered a chronic condition and people living with HIV needing antiretroviral treatments for life, taking fewer medicines over a lifetime has become an important...
According to another aspect of the main embodiment, injections must be administered by a healthcare professional. A complete dose requires 2 injections: one injection of cabotegravir and one injection of rilpivirine. Injections of the Combination are intended for intramuscular use only. Consider the ...